-
Je něco špatně v tomto záznamu ?
Biomedically relevant chemical constituents of Valeriana officinalis
Jiří Patočka, Jiří Jakl
Jazyk angličtina Země Česko
Typ dokumentu přehledy
NLK
Free Medical Journals
od 2003 do 2013
Freely Accessible Science Journals
od 2003 do 2013
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- alkaloidy farmakologie klasifikace terapeutické užití MeSH
- analgetika terapeutické užití MeSH
- antikonvulziva terapeutické užití MeSH
- anxiolytika terapeutické užití MeSH
- experimenty na zvířatech MeSH
- hypnotika a sedativa terapeutické užití MeSH
- iridoidy chemie MeSH
- kozlík (rostlina) chemie MeSH
- kyseliny pentanové chemie škodlivé účinky terapeutické užití MeSH
- lidé MeSH
- rostlinné extrakty chemie MeSH
- rostlinné přípravky aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- Valerianaceae chemie klasifikace MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- přehledy MeSH
Valerian is used to treat sleeping disorders, restlessness and anxiety, but it seemsonly to work when taken over long periods (several weeks). Some studies have demonstrated that valerian extracts interact with the GABA and benzodiazepine receptors. Valerian is also used traditionally to treat gastrointestinal pain and spastic colitis. There are no long term safety studies. Valerian contains over 150 chemical constituents and many of them are physiologically active, mainly pyridine alkaloids, some organic acids and terpenes, especially the so called valepotriates, esterified iridoid-monoterpenes. As valepotriates may be potential mutagens, valerian should only be used after consultation with a physician. Valerian medication is sometimes recommended as first line treatment when the benefit-risk relation requires it and is often indicated as transition medication during the discontinuation processes involving bromazepam, clonazepam and diazepam, among others.
Citace poskytuje Crossref.org
Lit.: 64
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10008314
- 003
- CZ-PrNML
- 005
- 20111210162031.0
- 008
- 101207s2010 xr e eng||
- 009
- AR
- 024 7_
- $a 10.2478/v10136-009-0002-z $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Patočka, Jiří, $d 1939- $7 jn20000401939
- 245 10
- $a Biomedically relevant chemical constituents of Valeriana officinalis / $c Jiří Patočka, Jiří Jakl
- 314 __
- $a Faculty of Health and Social Studies, University of South Bohemia, České Budějovice
- 504 __
- $a Lit.: 64
- 520 9_
- $a Valerian is used to treat sleeping disorders, restlessness and anxiety, but it seemsonly to work when taken over long periods (several weeks). Some studies have demonstrated that valerian extracts interact with the GABA and benzodiazepine receptors. Valerian is also used traditionally to treat gastrointestinal pain and spastic colitis. There are no long term safety studies. Valerian contains over 150 chemical constituents and many of them are physiologically active, mainly pyridine alkaloids, some organic acids and terpenes, especially the so called valepotriates, esterified iridoid-monoterpenes. As valepotriates may be potential mutagens, valerian should only be used after consultation with a physician. Valerian medication is sometimes recommended as first line treatment when the benefit-risk relation requires it and is often indicated as transition medication during the discontinuation processes involving bromazepam, clonazepam and diazepam, among others.
- 650 _2
- $a Valerianaceae $x chemie $x klasifikace $7 D028161
- 650 _2
- $a kozlík (rostlina) $x chemie $7 D014632
- 650 _2
- $a rostlinné extrakty $x chemie $7 D010936
- 650 _2
- $a rostlinné přípravky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D028321
- 650 _2
- $a alkaloidy $x farmakologie $x klasifikace $x terapeutické užití $7 D000470
- 650 _2
- $a kyseliny pentanové $x chemie $x škodlivé účinky $x terapeutické užití $7 D010421
- 650 _2
- $a experimenty na zvířatech $7 D032761
- 650 _2
- $a iridoidy $x chemie $7 D039823
- 650 _2
- $a hypnotika a sedativa $x terapeutické užití $7 D006993
- 650 _2
- $a antikonvulziva $x terapeutické užití $7 D000927
- 650 _2
- $a analgetika $x terapeutické užití $7 D000700
- 650 _2
- $a anxiolytika $x terapeutické užití $7 D014151
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Jakl, Jiří, $d 1981- $7 mzk2009502644
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $g Roč. 8, č. 1 (2010), s. 11-18 $x 1214-021X
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2010/01/02.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 8
- 990 __
- $a 20100409135453 $b ABA008
- 991 __
- $a 20110222092907 $b ABA008
- 999 __
- $a ok $b bmc $g 722209 $s 585298
- BAS __
- $a 3
- BMC __
- $a 2010 $b 8 $c 1 $d 11-18 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $a 2010-19/dkal